Cost-utility analysis of PCSK9 inhibitors for hypercholesterolemia: a Chinese healthcare perspective

ObjectiveTo evaluate the cost-utility of different dosing regimens of PCSK9 inhibitors, added to statin therapy, in patients with hypercholesterolemia or at high cardiovascular risk in China.MethodsA Markov cohort multistate-transition model was developed from the perspective of the Chinese healthca...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Dandan Hu, Xu Deng, Mengwen Feng, Xinyue Zhang, Qingfeng He, Tao Wang, Zhen Feng
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2025-11-01
coleção:	Frontiers in Pharmacology
Assuntos:	PCSK9 inhibitors hypercholesterolemia cost-utility pharmacoeconomics Markov model China
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1708701/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!